Kalytera Therapeutics

Kalytera identifies sites for planned GvHD clinical trials

Wednesday, April 26, 2017

Kalytera Therapeutics, a clinical-stage biopharmaceutical company developing next-generation cannabinoid- derived therapeutics, has developed the multicenter location component of the plan for the proposed clinical trials to evaluate cannabidiol (CBD) for the prevention and treatment of Graft versus Host Disease (GvHD). Kalytera is developing this clinical trial plan with the intent of obtaining FDA and EMEA approval for commercialization.

[Read More]